158 related articles for article (PubMed ID: 18783202)
1. Identification of BRAF inhibitors through in silico screening.
Luo C; Xie P; Marmorstein R
J Med Chem; 2008 Oct; 51(19):6121-6127. PubMed ID: 18783202
[TBL] [Abstract][Full Text] [Related]
2. Recent progress in the identification of BRAF inhibitors as anti-cancer agents.
El-Nassan HB
Eur J Med Chem; 2014 Jan; 72():170-205. PubMed ID: 24424304
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors of BRAF dimers using an allosteric site.
Cotto-Rios XM; Agianian B; Gitego N; Zacharioudakis E; Giricz O; Wu Y; Zou Y; Verma A; Poulikakos PI; Gavathiotis E
Nat Commun; 2020 Sep; 11(1):4370. PubMed ID: 32873792
[TBL] [Abstract][Full Text] [Related]
4. Structure-based de novo design and biochemical evaluation of novel BRAF kinase inhibitors.
Park H; Jeong Y; Hong S
Bioorg Med Chem Lett; 2012 Jan; 22(2):1027-30. PubMed ID: 22196123
[TBL] [Abstract][Full Text] [Related]
5. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, biological evaluation and molecular modeling of novel 1H-pyrazolo[3,4-d]pyrimidine derivatives as BRAF
Wang Y; Wan S; Li Z; Fu Y; Wang G; Zhang J; Wu X
Eur J Med Chem; 2018 Jul; 155():210-228. PubMed ID: 29886324
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
8. Identification of type II inhibitors targeting BRAF using privileged pharmacophores.
Zhang Q; Wang J; Wang F; Chen X; He Y; You Q; Zhou H
Chem Biol Drug Des; 2014 Jan; 83(1):27-36. PubMed ID: 24164966
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of novel 2,3-dihydropyrazino[1,2-a]indole-1,4-dione derivatives as antiproliferative EGFR and BRAF
Al-Wahaibi LH; Gouda AM; Abou-Ghadir OF; Salem OIA; Ali AT; Farghaly HS; Abdelrahman MH; Trembleau L; Abdu-Allah HHM; Youssif BGM
Bioorg Chem; 2020 Nov; 104():104260. PubMed ID: 32920363
[TBL] [Abstract][Full Text] [Related]
10. Development of Allosteric BRAF Peptide Inhibitors Targeting the Dimer Interface of BRAF.
Gunderwala AY; Nimbvikar AA; Cope NJ; Li Z; Wang Z
ACS Chem Biol; 2019 Jul; 14(7):1471-1480. PubMed ID: 31243962
[TBL] [Abstract][Full Text] [Related]
11. Identification of pyrazolo[1,5-a]pyrimidine-3-carboxylates as B-Raf kinase inhibitors.
Gopalsamy A; Ciszewski G; Hu Y; Lee F; Feldberg L; Frommer E; Kim S; Collins K; Wojciechowicz D; Mallon R
Bioorg Med Chem Lett; 2009 May; 19(10):2735-8. PubMed ID: 19362830
[TBL] [Abstract][Full Text] [Related]
12. Design and biological evaluation of novel triaryl pyrazoline derivatives with dioxane moiety for selective BRAF
Li HL; Su MM; Xu YJ; Xu C; Yang YS; Zhu HL
Eur J Med Chem; 2018 Jul; 155():725-735. PubMed ID: 29940463
[TBL] [Abstract][Full Text] [Related]
13. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel imidazole derivatives possessing terminal sulphonamides as potential BRAF
Ali EMH; Abdel-Maksoud MS; Ammar UM; Mersal KI; Ho Yoo K; Jooryeong P; Oh CH
Bioorg Chem; 2021 Jan; 106():104508. PubMed ID: 33280830
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel family of BRAF(V600E) inhibitors.
Qin J; Xie P; Ventocilla C; Zhou G; Vultur A; Chen Q; Liu Q; Herlyn M; Winkler J; Marmorstein R
J Med Chem; 2012 Jun; 55(11):5220-30. PubMed ID: 22537109
[TBL] [Abstract][Full Text] [Related]
16. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolopyridine inhibitors of B-Raf(V600E). Part 4: rational design and kinase selectivity profile of cell potent type II inhibitors.
Wenglowsky S; Moreno D; Laird ER; Gloor SL; Ren L; Risom T; Rudolph J; Sturgis HL; Voegtli WC
Bioorg Med Chem Lett; 2012 Oct; 22(19):6237-41. PubMed ID: 22954737
[TBL] [Abstract][Full Text] [Related]
18. Design and Synthesis of Type-IV Inhibitors of BRAF Kinase That Block Dimerization and Overcome Paradoxical MEK/ERK Activation.
Beneker CM; Rovoli M; Kontopidis G; Röring M; Galda S; Braun S; Brummer T; McInnes C
J Med Chem; 2019 Apr; 62(8):3886-3897. PubMed ID: 30977659
[TBL] [Abstract][Full Text] [Related]
19. Novel tricyclic pyrazole BRAF inhibitors with imidazole or furan central scaffolds.
Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Nourry A; Davies L; Manne HA; Friedlos F; Ogilvie L; Hedley D; Takle AK; Wilson DM; Pons JF; Coulter T; Kirk R; Cantarino N; Whittaker S; Marais R; Springer CJ
Bioorg Med Chem; 2010 Sep; 18(18):6934-52. PubMed ID: 20667740
[TBL] [Abstract][Full Text] [Related]
20. Potent BRAF kinase inhibitors based on 2,4,5-trisubstituted imidazole with naphthyl and benzothiophene 4-substituents.
Niculescu-Duvaz D; Niculescu-Duvaz I; Suijkerbuijk BM; Ménard D; Zambon A; Davies L; Pons JF; Whittaker S; Marais R; Springer CJ
Bioorg Med Chem; 2013 Mar; 21(5):1284-304. PubMed ID: 23376011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
